Reviva Pharmaceuticals (RVPH) to Release Earnings on Monday

Reviva Pharmaceuticals (NASDAQ:RVPH) will likely be issuing its quarterly earnings data before the market opens on Monday, April 21st. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. On average, analysts expect Reviva Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Reviva Pharmaceuticals Stock Performance

Reviva Pharmaceuticals stock opened at $0.78 on Friday. The stock’s 50 day simple moving average is $1.10 and its two-hundred day simple moving average is $1.40. The stock has a market cap of $36.57 million, a price-to-earnings ratio of -0.70 and a beta of 0.05. Reviva Pharmaceuticals has a fifty-two week low of $0.49 and a fifty-two week high of $4.28.

Wall Street Analyst Weigh In

Several brokerages have recently commented on RVPH. HC Wainwright decreased their price objective on shares of Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. Roth Mkm initiated coverage on Reviva Pharmaceuticals in a research report on Friday, January 10th. They issued a “buy” rating and a $7.00 price objective on the stock. D. Boral Capital cut their target price on Reviva Pharmaceuticals from $15.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Roth Capital raised Reviva Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 10th. Finally, Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research report on Friday, January 10th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $10.00.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.